← Back to Screener
Coherus Oncology, Inc. Common Stock (CHRS)
Price$1.90
Favorite Metrics
Price vs S&P 500 (26W)2.83%
Price vs S&P 500 (4W)13.17%
Market Capitalization$278.80M
P/E Ratio (Annual)1.66x
All Metrics
Book Value / Share (Quarterly)$0.50
P/TBV (Annual)11.62x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-41.53%
Cash Flow / Share (Quarterly)$-1.14
Price vs S&P 500 (YTD)29.75%
Gross Margin (TTM)67.24%
Net Profit Margin (TTM)398.43%
EPS (TTM)$1.46
10-Day Avg Trading Volume0.81M
EPS Excl Extra (TTM)$1.46
Revenue Growth (5Y)-38.41%
EPS (Annual)$1.43
ROI (Annual)149.90%
Gross Margin (Annual)67.24%
Net Profit Margin (5Y Avg)18.09%
Cash / Share (Quarterly)$1.42
P/E Basic Excl Extra (TTM)1.66x
Revenue Growth QoQ (YoY)-76.46%
EPS Growth (5Y)-1.96%
P/E Normalized (Annual)1.66x
ROA (Last FY)65.04%
Revenue Growth TTM (YoY)-84.20%
EBITD / Share (TTM)$-1.56
ROE (5Y Avg)-127.02%
Operating Margin (TTM)-429.51%
Cash Flow / Share (Annual)$-1.14
P/B Ratio4.57x
P/B Ratio (Quarterly)2.81x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)5.71x
Net Interest Coverage (TTM)-33.01x
ROA (TTM)42.39%
EV / EBITDA (TTM)3.95x
EPS Incl Extra (Annual)$1.43
Current Ratio (Annual)1.47x
Quick Ratio (Quarterly)1.36x
3-Month Avg Trading Volume1.82M
52-Week Price Return92.90%
P/E Incl Extra (TTM)1.66x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.12
P/S Ratio (Annual)6.61x
Asset Turnover (Annual)0.16x
52-Week High$2.62
Operating Margin (5Y Avg)-158.70%
EPS Excl Extra (Annual)$1.43
Tangible BV CAGR (5Y)-3.76%
26-Week Price Return6.82%
Quick Ratio (Annual)1.36x
13-Week Price Return13.94%
Total Debt / Equity (Annual)0.84x
Current Ratio (Quarterly)1.47x
Enterprise Value$240.995
Revenue / Share Growth (5Y)-42.44%
Asset Turnover (TTM)0.11x
Book Value / Share Growth (5Y)2.39%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.38x
Pretax Margin (Annual)-434.23%
Cash / Share (Annual)$1.42
3-Month Return Std Dev99.30%
Gross Margin (5Y Avg)52.25%
Net Income / Employee (TTM)$1
EBITDA CAGR (5Y)-13.04%
ROE (Last FY)275.39%
Net Interest Coverage (Annual)-15.59x
EPS Basic Excl Extra (Annual)$1.43
P/FCF (TTM)3.16x
Receivables Turnover (TTM)0.65x
Total Debt / Equity (Quarterly)0.84x
EPS Incl Extra (TTM)$1.46
Receivables Turnover (Annual)0.65x
ROI (TTM)160.33%
P/S Ratio (TTM)6.61x
Pretax Margin (5Y Avg)-166.75%
Revenue / Share (Annual)$0.36
Tangible BV / Share (Annual)$0.12
Price vs S&P 500 (52W)63.07%
P/E Ratio (TTM)1.66x
EPS Growth TTM (YoY)735.87%
Year-to-Date Return32.39%
5-Day Price Return13.94%
EPS Normalized (Annual)$1.43
ROA (5Y Avg)-13.87%
Net Profit Margin (Annual)398.43%
Month-to-Date Return11.24%
Cash Flow / Share (TTM)$-2.49
EBITD / Share (Annual)$-1.56
Operating Margin (Annual)-429.51%
LT Debt / Equity (Annual)0.84x
ROI (5Y Avg)-6.87%
P/E Excl Extra (TTM)1.66x
LT Debt / Equity (Quarterly)0.84x
EPS Basic Excl Extra (TTM)$1.46
P/TBV (Quarterly)11.62x
P/B Ratio (Annual)2.81x
Inventory Turnover (TTM)0.38x
Pretax Margin (TTM)-434.23%
Book Value / Share (Annual)$0.50
Price vs S&P 500 (13W)13.25%
Net Margin Growth (5Y)70.34%
Beta1.05x
P/FCF (Annual)1.90x
Revenue / Share (TTM)$0.35
ROE (TTM)250.83%
52-Week Low$0.71
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.09
4.17
4.17
4.17
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CHRSCoherus Oncology, Inc. Common Stock | 6.61x | -84.20% | 67.24% | -1.96% | $1.90 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Coherus Oncology is a commercial-stage biotechnology company with LOQTORZI, an approved PD-1 inhibitor, and a pipeline of two mid-stage clinical candidates. The company is expanding LOQTORZI's use in nasopharyngeal cancer and exploring combination therapies with its pipeline candidates and industry partners. Key assets include LOQTORZI, CHS-114, and Casdozokitug, targeting liver, lung, head and neck, and other cancers.